343 related articles for article (PubMed ID: 27537383)
1. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
2. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
[TBL] [Abstract][Full Text] [Related]
3. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
5. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
6. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
Barbier RH; McCrea EM; Lee KY; Strope JD; Risdon EN; Price DK; Chau CH; Figg WD
Sci Rep; 2021 May; 11(1):10765. PubMed ID: 34031488
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
9. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
Wright JL; Kwon EM; Ostrander EA; Montgomery RB; Lin DW; Vessella R; Stanford JL; Mostaghel EA
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):619-27. PubMed ID: 21266523
[TBL] [Abstract][Full Text] [Related]
10. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Sartor AO
J Hematol Oncol; 2011 Apr; 4():18. PubMed ID: 21513551
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
[TBL] [Abstract][Full Text] [Related]
12. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
13. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
14. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
[TBL] [Abstract][Full Text] [Related]
15. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
16. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.
Sissung TM; Ley AM; Strope JD; McCrea EM; Beedie S; Peer CJ; Shukla S; van Velkinburgh J; Reece K; Troutman S; Campbell T; Fernandez E; Huang P; Smith J; Thakkar N; Venzon DJ; Brenner S; Lee W; Merino M; Luo J; Jager W; Price DK; Chau CH; Figg WD
Mol Cancer Res; 2017 Aug; 15(8):1096-1105. PubMed ID: 28389619
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
18. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
19. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
